Nemaura Medical (NMRD)

Overall impact
B (69)

Commentary

Nemaura Medical is a strong overall performer. With a 'B' rating of 69.2 for overall impact (81st percentile compared to all companies), Nemaura Medical ranks 35th out of 103 industry peers, behind MyMD Pharmaceuticals, Alphatec, electroCore and 31 others, and ahead of Waters, Biolase, Biomerica and 65 others. On top material causes for Nemaura Medical's industry (Healthcare Equipment), Nemaura Medical performs well in Access to Affordable Healthcare (85.1 score), Improved Mental Health (81.0) and Conflict Free Mineral Production (96.0) and performs poorly in Sanitation Access (38.6 score).
Impact
Cause NMRD
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
36
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Ny, United States
Share classes
NMRD
Description
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring systems in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, wellness guidance notes that provide prompts and educate users on factors affecting blood sugar profiles. Additionally, it conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Material causes
Ethos considers the following causes material for Nemaura Medical, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.